Robert Justice

Medicine · Health Sciences

49h-index14.3kcitations94works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(17), Cancer Treatment and Pharmacology(17), Lymphoma Diagnosis and Treatment(16), Colorectal Cancer Treatments and Studies(12), Lung Cancer Treatments and Mutations(11)

Publications94 total

Data from FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
2023Open Access
Data from FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
2023Open Access
Supplementary Table 1 from FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
2023Open Access
Supplementary Table 1 from FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
2023Open Access
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
Clinical Cancer Research·2015· 159 cited
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Clinical Cancer Research·2015· 341 cited
FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
Clinical Cancer Research·2015· 183 cited
FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
Clinical Cancer Research·2015· 145 citedOpen Access
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
Clinical Cancer Research·2015· 104 cited
Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities
Molecular Oncology·2014· 26 citedOpen Access
First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
Clinical Cancer Research·2014· 151 citedOpen Access
FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
The Oncologist·2014· 283 citedOpen Access
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
Clinical Cancer Research·2014· 209 cited
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Clinical Cancer Research·2014· 337 cited
U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations
The Oncologist·2014· 140 citedOpen Access
Targeted therapy approvals: Summary and future directions.
Journal of Clinical Oncology·2014
FDA breakthrough therapy designation of oncology products: The first-year experience.
Journal of Clinical Oncology·2014
Special protocol assessments: 10 years of experience in FDA’s Office of Hematology and Oncology Products.
Journal of Clinical Oncology·2014· 1 cited
U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
Clinical Cancer Research·2014· 41 cited
Reply to Letter to the Editor: Local Evaluation and Blinded Central Review Comparison a Victim of Meta-analysis Shortcomings
Therapeutic Innovation & Regulatory Science·2014
page 1 of 5Next →

Frequent Co-authors

Richard Pazdur(47), Rajeshwari Sridhara(23), Shenghui Tang(17), Ann T. Farrell(14), John R. Johnson(11), Brian Booth(11), Amna Ibrahim(11), Patricia Cortazar(10), Gideon M. Blumenthal(9), Martin H. Cohen(9), Ramzi Dagher(8), Robert C. Kane(7), Haleh Saber(7), Julie Bullock(7), Nitin Mehrotra(7), Patricia Keegan(7), Lijun Zhang(6), David E. Morse(6), Yang‐Min Ning(6), Edvardas Kaminskas(5)